Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program
20 Luglio 2020 - 07:00AM
Saint-Herblain (France), July 20, 2020 –
Valneva SE, a specialty vaccine company focused on prevention
against diseases with major unmet needs, today confirmed its
participation in the UK government COVID-19 vaccine response
program.
Valneva has reached agreement in principle with
the UK government to provide up to 100m doses of its SARS-CoV-2
vaccine candidate, to be manufactured at its facilities in
Livingston, Scotland. The UK government is expected to
contribute to UK clinical studies costs and is negotiating funding
to expand Valneva’s Scottish facility. As part of its broader
COVID-19 response, Valneva plans to further invest in its
manufacturing facility in Livingston, Scotland and also in Solna,
Sweden.
Thomas Lingelbach, CEO of Valneva,
commented, “We are delighted to have been selected to participate
in this important program with the UK government. This recognizes
the strong track record and capabilities that we have built in the
last fifteen years both in the UK and beyond. Our Livingston
facility has been FDA approved for over a decade and we have a
strong team both there and in Solna. We also envisage manufacturing
vaccines to support the need for prevention of COVID-19 beyond the
UK.”
On April 22, 2020, Valneva announced that it is
developing VLA2001, an inactivated whole virus vaccine candidate
against the novel coronavirus SARS-CoV-2. VLA2001 leverages
Valneva’s well-established platform for IXIARO®, its vaccine
approved for active immunization for the prevention of Japanese
encephalitis. The Company is also collaborating with Dynavax to
evaluate the potential use of its CpG 1018 adjuvant as part of the
VLA2001 vaccine. This vaccine is expected to enter clinical
studies by the end of 2020 and to potentially reach regulatory
approval in the second half of 2021.
About the Novel Coronavirus SARS-CoV-2 and
COVID-19 DiseaseSARS-CoV-2 is a new coronavirus identified in
late 2019 and belongs to a family of enveloped RNA viruses that
include MERS and SARS, both of which caused serious human
infections of respiratory system. The virus, which causes a disease
named COVID-19, has never before been found in humans. Since this
outbreak was first reported in late-2019, the virus has infected
over 14 million people and has caused over 600,000 reported deaths
(as of July 18, 2020). It has been declared a pandemic by the World
Health Organization (WHO). Currently, there is no vaccine available
for COVID-19.
About VLA 2001VLA2001 is a Vero-cell
based, highly purified inactivated vaccine candidate against the
SARS-COV-2 virus, leveraging the manufacturing technology for
Valneva’s Japanese Encephalitis Vaccine. The Company has designed a
process that largely uses this platform in regards to upstream- and
downstream process steps as plug-and-play with moderate
adjustments. The process includes inactivation with BPL to preserve
the native structure of the S protein. The combination with CpG
1018 is expected to induce a strong immune response and has the
potential to generate high titers of neutralizing antibodies.
About Valneva SEValneva is a specialty
vaccine company focused on prevention against diseases with major
unmet needs. Valneva’s portfolio includes two commercial vaccines
for travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various vaccines in development including
unique vaccines against Lyme disease and chikungunya. Valneva has
operations in Austria, Sweden, the United Kingdom, France, Canada
and the US with over 500 employees. For more information,
visit www.valneva.com and follow the Company on LinkedIn.
Valneva
Investor and Media ContactsDavid LawrenceChief Financial
Officer+447908627213 Laetitia Bachelot-FontaineDirector
Investor Relations & Corporate CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
|
Valneva Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_07_20_VLA_COVID-19_UK_PR_EN